1. Home
  2. REVB vs NAOV Comparison

REVB vs NAOV Comparison

Compare REVB & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • NAOV
  • Stock Information
  • Founded
  • REVB 2020
  • NAOV 2003
  • Country
  • REVB United States
  • NAOV United States
  • Employees
  • REVB N/A
  • NAOV N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • NAOV Industrial Specialties
  • Sector
  • REVB Health Care
  • NAOV Health Care
  • Exchange
  • REVB Nasdaq
  • NAOV Nasdaq
  • Market Cap
  • REVB 2.3M
  • NAOV 2.4M
  • IPO Year
  • REVB N/A
  • NAOV N/A
  • Fundamental
  • Price
  • REVB $4.31
  • NAOV $0.38
  • Analyst Decision
  • REVB
  • NAOV
  • Analyst Count
  • REVB 0
  • NAOV 0
  • Target Price
  • REVB N/A
  • NAOV N/A
  • AVG Volume (30 Days)
  • REVB 175.9K
  • NAOV 6.7M
  • Earning Date
  • REVB 03-21-2025
  • NAOV 04-07-2025
  • Dividend Yield
  • REVB N/A
  • NAOV N/A
  • EPS Growth
  • REVB N/A
  • NAOV N/A
  • EPS
  • REVB N/A
  • NAOV N/A
  • Revenue
  • REVB N/A
  • NAOV $3,291,000.00
  • Revenue This Year
  • REVB N/A
  • NAOV N/A
  • Revenue Next Year
  • REVB N/A
  • NAOV N/A
  • P/E Ratio
  • REVB N/A
  • NAOV N/A
  • Revenue Growth
  • REVB N/A
  • NAOV 227.79
  • 52 Week Low
  • REVB $3.34
  • NAOV $0.36
  • 52 Week High
  • REVB $69.44
  • NAOV $1.27
  • Technical
  • Relative Strength Index (RSI)
  • REVB 40.86
  • NAOV 39.60
  • Support Level
  • REVB $3.80
  • NAOV $0.36
  • Resistance Level
  • REVB $4.54
  • NAOV $0.71
  • Average True Range (ATR)
  • REVB 0.37
  • NAOV 0.06
  • MACD
  • REVB 0.18
  • NAOV -0.00
  • Stochastic Oscillator
  • REVB 68.13
  • NAOV 6.19

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About NAOV NanoVibronix Inc.

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Share on Social Networks: